skip to content »

Nanotechnology based assays for validating protein biomarkers

nanotechnology based assays for validating protein biomarkers-76

Ask your oncologist about the use of tumor markers for your diagnosis, and how markers are combined with other strategies for diagnosis and monitoring of cancer.

nanotechnology based assays for validating protein biomarkers-88

We compared the results to those obtained using an electrochemiluminescence assay on the Mesoscale Discovery (MSD) platform, to a traditional ELISA, and to a MILLIPLEX® MAP assay for the Luminex® platform. GYRKIM1-20K) were developed and used for biomarker quantitation, according to the protocols supplied with the kits.New markers, such as KIM-1 and Clusterin, help detect damage to the kidneys and offer clues to specific tissue injury in a timelier manner.We developed rat KIM-1 and clusterin Gyro Mark™ HT biomarker immunoassays, the first two commercially available toxicity assay kits for the Gyrolab® x P Workstation platform.The pharmacology industry is beginning to recognize that most drugs work in only a subset of the patient treatment population.Industry also recognizes that if drugs can be tailored for the right patient population, not only can the clinical trials to test the drug be smaller, more efficient and cheaper, but a premium price can be charged for a drug that is much more likely to work in the patients who receive it.Other research approaches may determine better tumor markers.

There are not only many elements but also many technologies that need to be verified and standardized.

Since most cancer cells have changes in their DNA, studying patterns of DNA changes through genomics research may reveal improved tumor markers.

Instead of just one protein, proteomic research assessing patterns in proteins can allow doctors to test thousands of proteins at once, which may reveal the groups of the most common proteins associated with different types of cancer.

A leading cause of failure in any drug development program is organ toxicity, such as in the kidney.

Traditional nephrotoxicity biomarkers may show insufficient tissue specificity and often cannot be detected until damage is irreversible.

The National Cancer Institute's Alliance for Nanotechnology in Cancer has released a special feature paper titled Nanotechnology-Based Assays for Validating Protein Biomarkers.